November 5, 2019 06:56 AM EST
Pharma
FDA+

Is FDA do­ing enough to bring biosim­i­lars to mar­ket? Ex­perts dis­cuss

Zachary Brennan

Senior Editor

As the num­ber of biosim­i­lar ap­provals con­tin­ues to rise in the US, the num­ber of biosim­i­lar launch­es con­tin­ues to lag, but ex­perts ex­plained how this …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times